October 7, 2026

New NeoLINK^® Enhancement – Expected Completion Date

At NeoGenomics, we are continually looking for ways to make it easier for you and your team to manage patient care, reduce administrative burden, and access the information you need when you need it. As part of that commitment, we are pleased to announce a new NeoLINK enhancement that was made available October 5th 2026. One of the most common requests we hear from providers and practice staff is for greater visibility into when test results are expected to be available. While NeoLINK currently displays a static Due Date based on our standard published turnaround times, that date does not always reflect changes that can occur during the testing process.  The new Expected Completion Date feature provides dynamic real-time visibility into when a case is expected to be resulted. Benefits include: • Greater visibility into order status • More accurate expectations for result availability • Earlier awareness of potential delays • Improved planning and workflow management for your staff • Better communication with providers and patients This enhancement is part of our ongoing commitment to improving the NeoLINK experience and providing greater transparency throughout the testing process. We encourage you to begin leveraging the Estimated Completion Date field as part of your daily workflow and welcome any feedback you may have as we continue to enhance the experience.  We remain committed to delivering solutions that reduce friction, improve transparency, and help support exceptional patient care. Please note that Estimated Completion Dates for Send Outs, Histology Consults, Morphology, FISH (Tech Only), and Cytogenetics cases will be introduced in a future release. Visit our FAQs for additional information regarding this enhancement.

Order Supplies Online Anytime Through Our Supply Order Portal

As part of our ongoing mission to enhance the tools and services available to you and simplify your experience, we are excited to announce a new and convenient way to order your NeoGenomics supplies. You can now submit supply orders online through our Supply Order Portal, giving you the flexibility to order specimen transport kits, requisition forms, and other supplies whenever it is most convenient for your team. Benefits of the Supply Order Portal: Order supplies 24/7 at your convenience Easily request specimen transport kits and requisition forms Ship to your primary location or an alternate address View recently ordered items for faster reordering View the status of supply orders and specimen shipments Track the status of specimens shipped to NeoGenomics via FedEx. To access to our Supply Order Portal, please contact your Client Success Specialist, or our Client Services team at 866.776.5907, option 3.  You may also request access through our website by visiting Contact NeoGenomics. We look forward to providing you with a more convenient, self-service approach to managing your supply ordering needs.

More comprehensive insights from the heme tests you already trust

Neo Comprehensive® – Heme Cancers and Neo Comprehensive® – Myeloid Disorders  now offer broader genomic coverage, increased reporting sensitivity, and faster turnaround times, providing greater confidence while maintaining the trusted testing you rely on. What's new: Expanded guideline-driven genomic coverage: UBA1 added to support complex MDS cases Expanded variant allele frequency (VAF) reporting: Hotspot mutations and 50 CHIP-associated genes now reported at 3% VAF Faster results: Comprehensive results in a single report delivered in as few as 8 days* What this means for you: Greater visibility into low-frequency variants Broader genomic coverage through UBA1 inclusion More comprehensive molecular characterization Faster access to comprehensive genomic insights The same trusted quality and expertise from NeoGenomics Enhanced support for complex patient management decisions Additionally, to support ongoing optimization of assay content, a small number of low-clinical-utility targets, including SBDS, CHD1, and ZEB2, will be removed while overall coverage and performance have been enhanced. *Turnaround time for these tests is 8–11 days

c-MET CDx for NSCLC

NeoGenomics is proud to offer a c-MET CDx for NSCLC to support precision oncology in non-small cell lung cancer (NSCLC). This advanced immunohistochemistry (IHC) assay enables precise detection of HGF Receptor (c-Met) protein expression, empowering oncologists to identify patients with NSCLC who may benefit from a new targeted therapy. Learn how HGF Receptor (c-Met)  testing can transform your approach to lung cancer care. We invite you to visit us online.